Zolmitriptan
As of the edition of 20 October 2026, Zolmitriptan is a small molecule: marketed, first approved in 1997 (FR); acts on HTR1B and HTR1D.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Zomig
- First approved
- 28 August 1997 (FR)
- Approvals on record
- 9 in 4 regions
- Holder of the most recent approval
- GRÜNENTHAL DO BRASIL FARMACÊUTICA LTDA.; 6 holders in all
- Registered trials
- 15, 0 stopped early
- Disease areas
- Nervous system; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Zolmitriptan.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 8 | 8 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| Phase 4 | 4 | 3 | 0 | 0 |
| All trials | 15 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Originator, Applicant, Later holder and Lead sponsor of trials | 1997 to now |
| Amneal Pharmaceuticals | Acquired holder and Lead sponsor of trials | 2003 to now |